Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study (BLISS)
Systemic Inflammatory Response Syndrome, Oliguria, Renal Impairment
About this trial
This is an interventional treatment trial for Systemic Inflammatory Response Syndrome focused on measuring sodium bicarbonate, serum neutrophil gelatinase associated lipocalin, renal impairment, renal failure, systemic inflammatory response syndrome, defined, by serum NGAL ≥ 100 ng/ml.
Eligibility Criteria
Inclusion Criteria:
- Consent obtained
- Diagnosis of SIRS. Requires any TWO of:
temperature > 38°C or < 36°C OR heart rate > 90 beats/min OR respiratory rate > 20 breaths/min. PaCO2 < 32 mm Hg OR alteration of white blood cell count > 12,000 cells/mm3, < 4,000 cells/mm3, or the presence of > 10% immature neutrophils
- elevated lipocalin level
- Arterial line already in place
- Central venous catheter already in place
- Age ≥ 18 years
- Within 24 hours of admission to the ICU
Exclusion Criteria:
- Unlikely to remain in ICU for >72 hours
- Moribund patient
- Pre-existing CKD, transplant or ESRD
- Receiving (or about to receive) continuous renal replacement therapy for acute renal failure at time of enrolment
- Diagnosis of acute GN, AIN, vasculitis or post-renal aetiology
- Known/suspected study allergy to sodium bicarbonate
- Enrolling physician concern about patient enrolment
Sites / Locations
- Austin Hospital
- Royal Melbourne Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Sodium bicarbonate
Sodium chloride
sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr